comparemela.com
Home
Live Updates
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update : comparemela.com
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studiesPhase
Related Keywords
Germany
,
Australia
,
Philippines
,
United States
,
Netherlands
,
United Kingdom
,
Belgium
,
Boston
,
Massachusetts
,
Canada
,
Panama
,
Spain
,
Switzerland
,
German
,
Ulrike Gnad Vogt
,
Myriam Mendila
,
Sarah Fakih
,
Franz Werner Haas
,
Pierre Kemula
,
Development Officer
,
Rna Vaccine Program
,
Curevac Inc
,
Genentech
,
German Regional Court
,
Novartis
,
Exchange Commission
,
Pfizer
,
Corporate Development
,
Corporate Communications
,
Curevac Corporate Services Gmb
,
Mrna Technology
,
Clinical Development
,
Frame Cancer Therapeutics
,
Chief Development Officer
,
Chief Executive Officer
,
Frame Cancer
,
Chief Financial Officer
,
Broad Second Generation
,
Jointly Developed
,
Intellectual Property
,
Frame Cancer Therapeutics Accelerates Oncology
,
Senior Vice President Area Head Oncology
,
Chief Development
,
Second Quarter
,
First Half
,
Cov Phase
,
Finance Income
,
Vice President Corporate Communications
,
Curevac Manufacturing Gmbh
,
Curevac Swiss
,
Curevac Corporate Services Gmbh
,
Curevac Belgium
,
Condensed Consolidated Profit
,
Operating Expenses
,
Curevac
,
Nnounces
,
Financial
,
Results
,
Second
,
Quarter
,
First
,
Calf
,
022
,
Rovides
,
Business
,
Update
,
comparemela.com © 2020. All Rights Reserved.